Choose Your Country or Region

Australia
Austria
Belgium
Canada
China
Czech Republic
Denmark
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Luxembourg
Malaysia
Netherlands
New Zealand
Norway
Poland
Qatar
Romania
Saudi Arabia
Singapore
Spain
Sweden
Switzerland
Taiwan
Turkey
United Kingdom
United States
Azacitidine (5-Azacytidine) of Selleck (Japan)

Azacitidine (5-Azacytidine)

DNA Methyltransferase inhibitor

Catalog No.S1782 Purity:99.92%

research use only

Azacitidine (5-Azacytidine, 5-AzaC, Ladakamycin, AZA, 5-Aza, CC-486,NSC 102816) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases. Azacitidine induces mitochondrial apoptosis and autophagy.

Azacitidine (5-Azacytidine) Chemical Structure

Molecular Weight: 244.2

Purity & Quality Control

Batch: Purity: 99.92%

99.92

Azacitidine (5-Azacytidine) Related Products

Related Targets	TET DNMT1 DNMT3	Click to Expand
Related Products	RG108 SGI-1027 Zebularine (NSC 309132) Gamma-Oryzanol Bobcat339 hydrochloride CM272 GSK3685032 β-thujaplicin	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Apoptosis Compound Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	Click to Expand

Signaling Pathway

DNA Methyltransferase Signaling Pathway

Cell Culture and Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	Growth Inhibition Assay	0.1-50 μM	12-72 h		inhibits cell growth in a dose dependent manner	26133246
Jurkat	Growth Inhibition Assay	0.1-50 μM	12-72 h		inhibits cell growth in a dose dependent manner	26133246
CA46	Function Assay	20 µM	48 h		increases PTPL1 mRNA expression	26133246
Raji	Function Assay	15 µM	48 h		increases PTPL1 mRNA expression	26133246
Jurkat	Function Assay	3.5 µM	48 h		increases PTPL1 mRNA expression	26133246
MDA-MB-231	Function Assay	1/2.5/5 μM	48 h		decreases the PTPN12 expression at the concerntration of 5 μM 48 h	25817229
MDA-MB-231	Function Assay	1/2.5/5 μM	48 h		increases the levels of E-cadherin mRNA at the concerntration of 2.5 μMfor 48 h	25817229
MDA-MB-231	Function Assay	1/2.5/5 μM	24/48 h		induces significant PARP cleavage after 48 h	25817229
MCF-7	Function Assay	1/2.5/5 μM	24/48 h		increases PARP cleavage	25817229
MDA-MB-231	Function Assay	1/2.5/5 μM	24/48 h		increases the expression of miRNA-124 at the concerntration of 5 μM	25817229
A498	Function Assay	10 µM	72 h		induces the ADAMTS18 gene expression	25569086
CaKI-2	Function Assay	10 µM	72 h		induces the ADAMTS18 gene expression	25569086
Ketr-3	Function Assay	10 µM	72 h		induces the ADAMTS18 gene expression	25569086
A253	Function Assay	10 µM	0-4 d		increases the mRNA expression level of the M3R after 24 h	25485536
A253	Function Assay	10 µM	72 h		increases the expression level of the M3R in both membrane and cytosolic preparations	25485536
A253	Function Assay	10 µM	0-4 d		reduces the 5-methylcytosine content	25485536
PC3	Function Assay	0.2 μM	4 d		increases the gene expression of IGFBP7, SFRP1 and SLC6A15 combined with GSK126	25477340
MCF7	Function Assay	0.3 μM	4 d		increases the gene expression of IGFBP7, SFRP1 and SLC6A15 combined with GSK126	25477340
PC3	Growth Inhibition Assay	0.2 μM	4 d		decreases the cell growth to 20.3% combined with GSK126	25477340
MCF7	Growth Inhibition Assay	0.3 μM	4 d		decreases the cell growth 24.8% combined with GSK126	25477340
BGC-823	Function Assay	5 μM	72 h		decreases the PRL-3 protein level signifcantly	25475733
MKN28	Function Assay	5 μM	72 h		decreases the PRL-3 protein level signifcantly	25475733
SGC-7901	Function Assay	5 μM	72 h		decreases the PRL-3 protein level signifcantly	25475733
MKN45	Function Assay	5 μM	72 h		decreases the PRL-3 protein level signifcantly	25475733
BGC-823	Function Assay	5 μM	72 h		decreases the mRNA expression of PRL-3 significantly	25475733
MKN28	Function Assay	5 μM	72 h		decreases the mRNA expression of PRL-3 significantly	25475733
SGC-7901	Function Assay	5 μM	72 h		decreases the mRNA expression of PRL-3 significantly	25475733
MKN45	Function Assay	5 μM	72 h		decreases the mRNA expression of PRL-3 significantly	25475733
HREC	Function Assay	5/10 μM	48 h		induces PEDF in a dose-dependent manner	25352747
HRPE	Function Assay	5/10 μM	48 h		induces PEDF in a dose-dependent manner	25352747
HREC	Function Assay	5/10 μM	48 h		down-regulates of VEGF, ICAM-1 (not protein level in HRPE cells), IL-1β dose-dependently	25352747
HRPE	Function Assay	5/10 μM	48 h		down-regulates of VEGF, IL-1β, and MMP2 dose-dependently	25352747
MSCs	Function Assay	10 μM	24 h		promotes the commitment of MSCs to myocardial differentiation	25351395
HL-60	Function Assay	5 μM	72 h	DMSO	significantly upregulates ZNF382 expression	25319049
MV4-11	Function Assay	5 μM	72 h	DMSO	significantly upregulates ZNF382 expression	25319049
A2780	Function Assay	5 µM	7 d		increases DNA methylation level	25299694
CP70	Function Assay	5 µM	7 d		increases DNA methylation level	25299694
A2780	Function Assay	5 µM	7 d		weakens the level of methylation	25299694
CP70	Function Assay	5 µM	7 d		weakens the level of methylation	25299694
OCM3	Growth Inhibition Assay	0.5/1/2 μM	7 d	DMSO	inhibits cell growth in a dose dependent manner	25146981
92.1	Growth Inhibition Assay	0.5/1/2 μM	7 d	DMSO	inhibits cell growth in a dose dependent manner	25146981
OCM1	Growth Inhibition Assay	0.5/1/2 μM	7 d	DMSO	inhibits cell growth in a dose dependent manner	25146981
OMM1	Growth Inhibition Assay	0.5/1/2 μM	7 d	DMSO	inhibits cell growth in a dose dependent manner	25146981
Mel 285	Growth Inhibition Assay	0.5/1/2 μM	7 d	DMSO	inhibits cell growth in a dose dependent manner	25146981
Mel 290	Growth Inhibition Assay	0.5/1/2 μM	7 d	DMSO	inhibits cell growth in a dose dependent manner	25146981
OCM3	Function Assay	0.5/1 μM	48 h	DMSO	decreases clonogenicity dose-dependently	25146981
92.1	Function Assay	0.5/1 μM	48 h	DMSO	decreases clonogenicity dose-dependently	25146981
OCM1	Function Assay	0.5/1 μM	48 h	DMSO	decreases clonogenicity dose-dependently	25146981
OMM1	Function Assay	0.5/1 μM	48 h	DMSO	decreases clonogenicity dose-dependently	25146981
Mel 285	Function Assay	0.5/1 μM	48 h	DMSO	decreases clonogenicity dose-dependently	25146981
Mel 290	Function Assay	0.5/1 μM	48 h	DMSO	decreases clonogenicity dose-dependently	25146981
OCM3	Function Assay	0.5/1 μM	48 h	DMSO	decreases invasion dose dependently	25146981
Mel 290	Function Assay	0.5/1 μM	48 h	DMSO	decreases invasion dose dependently	25146981
OMM1	Function Assay	0.5/1 μM	48 h	DMSO	decreases invasion dose dependently	25146981
OCM1	Cell Viability Assay	0.5/1 μM	5 d	DMSO	decreases radiation-induced cell viability inhibition	25146981
92.1	Cell Viability Assay	0.5/1 μM	5 d	DMSO	decreases radiation-induced cell viability inhibition	25146981
OCM1	Function Assay	0.5/1 μM	48 h	DMSO	causes global DNA hypomethylation at L-1 repeat loci	25146981
OCM3	Function Assay	0.5/1 μM	48 h	DMSO	causes global DNA hypomethylation at L-1 repeat loci	25146981
92.1	Function Assay	0.5/1 μM	48 h	DMSO	causes global DNA hypomethylation at L-1 repeat loci	25146981
IMR32	Function Assay	3 μM	72 h	DMSO	induces p19-INK4d expression significantly	25104850
IMR5-75	Function Assay	3 μM	72 h	DMSO	induces p19-INK4d expression significantly	25104850
Be(2)-C	Function Assay	3 μM	72 h	DMSO	induces p19-INK4d expression significantly	25104850
Bxpc-3	Growth Inhibition Assay	5/10 μM	24/48/72 h		inhibits the proliferation of Bxpc-3 cells in time- and concentration-dependent manners	25061731
Bxpc-3	Apoptosis Assay	5/10 μM	24/48/72 h		induces apoptosis in time- and concerntration manners	25061731
Bxpc-3	Function Assay	5/10 μM	24/48/72 h		decreases β-catenin expression after 24 h	25061731
Bxpc-3	Function Assay	5/10 μM	24/48/72 h		decreases cyclinD1 expression at the concerntration of 10 μM	25061731
Bxpc-3	Function Assay	5/10 μM	24/48/72 h		down-regulateS c-myc mRNA expression in time- and concentration-dependent manners	25061731
HL-60	Growth Inhibition Assay	1.0 μM	48 h		significantly inhibits HL-60 cell growth	25051119
HL-60	Function Assay	1.0 μM	48 h		increases p21WAF1/CIP1 and caspase-3 expression	25051119
HL-60	Function Assay	1.0 μM	48 h		decreases Bcl-xL expression significantly	25051119
HuTu-80	Function Assay	1/5/10 μM	48/72 h		increases the expression of human NPC1L1 mRNA in a dose-dependent manner	24904062
Caco2	Function Assay	10 μM	48 h		increases NPC1L1 expression	24904062
HepG2	Function Assay	0-25 μM	24 h		decreases subtilisin/kexin type 9 (PCSK9) protein levels dose dependently	24855646
HepG2	Function Assay	0-25 μM	24 h		increases low density lipoprotein receptor (LDLR) gene expression	24855646
HepG2	Function Assay	10 μm	0-24 h		decreases PCSK9 and HMGCR expression and increases LDLR expression after 6 h	24855646
HepG2	Function Assay	10 μm	24 h		promotes cytosolic neutral lipid accumulation independently of exogenous lipoproteins	24855646
HepG2	Function Assay	10 μm	24 h		prevents SREBP processing	24855646
HC45	Function Assay	5µM	4 d		reduces the methylation levels of WIF1, P16, CXCL14, NKX2–3, CDH1, LAMA1, and CTNNB1	24762809
CNDT2	Function Assay	5µM	4 d		reduces the methylation levels of WIF1, P16, CXCL14, NKX2–3, CDH1, LAMA1, and CTNNB1	24762809
CNDT2	Function Assay	5µM	4 d		increases gene expression of WIF1, P16, CDH1, LAMA1, and CTNNB1	24762809
T-cells	Growth Inhibition Assay	5/20 μM	0-48 h		inhibits cell growth in a dose dependent manner	24757283
CD3+ T-cells	Function Assay	5/20 μM	48 h		upregulates p15 expression	24757283
CD4+ T-cells	Function Assay	5/20 μM	48 h		upregulates p15 expression	24757283
CD8+ T-cells	Function Assay	5/20 μM	48 h		upregulates p15 expression	24757283
CD3+ T-cells	Function Assay	5/20 μM	48 h		upregulates the expression of FOXP3	24757283
CD4+ T-cells	Function Assay	5/20 μM	48 h		upregulates the expression of FOXP3	24757283
CD4+ T-cells	Function Assay	5/20 μM	48 h		reduces TBET1 mRNA expression	24757283
CD4+ T-cells	Function Assay	5/20 μM	48 h		upregulates the expression of RORγt	24757283
CD4+ T-cells	Function Assay	5/20 μM	48 h		inhibits memory T-cells	24757283
CD8+ T-cells	Function Assay	5/20 μM	48 h		inhibits memory T-cells	24757283
CD3+ T-cells	Function Assay	5 μM	48 h		reduces long-term memory cell phenotype	24757283
U937	Apoptosis Assay	10 μM	72 h		induces apoptosis significantly	24680865
HL-60	Apoptosis Assay	10 μM	72 h		induces apoptosis significantly	24680865
MCF7	Function Assay	5 μM	48 h		displays selective toxicity toward suspended MCF-7 cells	24633350
MCF7	Function Assay	10 μM	24 h		induces the cleavage of caspase 7 and PARP	24633350
MCF7	Function Assay	0–0.5 μM	7 d		inhibits the growth MCF-7 tumorspheres in suspension cultures	24633350
MCF7	Function Assay	0.5 μM	14 d		reduces the size of MCF-7 colonies embedded in soft agar	24633350
MCF7	Function Assay	0.05–20 μM	1 d		reduces the clonal survival of MCF-7 cells in monolayer cultures	24633350
T47D	Function Assay	0.5 μM	4 d		inhibits tumorsphere formation	24633350
MCF7	Function Assay	0.5–10 μM	48 h		inhibits the gap closure in the wound healing assay	24633350
MCF7	Function Assay	0/10 μM	24 h		inhibits the activity of MMP9	24633350
MDA-MB-231	Function Assay	0.5–10 μM	36 h		inhibits the migration	24633350
SKM1-S	Antiproliferative assay		48 hrs		Antiproliferative activity against human SKM1-S cells after 48 hrs by XTT assay, IC50 = 0.5 μM.	28094938
SKM1-S	Antiproliferative assay		48 hrs		Antiproliferative activity against human SKM1-S cells after 48 hrs by DAPI-staining-based flow cytometric method, EC50 = 0.51 μM.	28094938
A427	Antiproliferative assay		96 hrs		Antiproliferative activity against human A427 cells after 96 hrs by crystal violet assay, IC50 = 0.63 μM.	18434163
KYSE70	Antiproliferative assay		96 hrs		Antiproliferative activity against human KYSE70 cells after 96 hrs by crystal violet assay, IC50 = 1.59 μM.	18434163
5637	Antiproliferative assay		96 hrs		Antiproliferative activity against human 5637 cells after 96 hrs by crystal violet assay, IC50 = 1.73 μM.	18434163
HT-29	Antiproliferative assay		96 hrs		Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50 = 3.8 μM.	2778449
P388	Antiproliferative assay		48 hrs		Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay, IC50 = 5 μM.	2778449
MCF7	Antiproliferative assay		96 hrs		Antiproliferative activity against human MCF7 cells after 96 hrs by crystal violet assay, IC50 = 6.78 μM.	18434163
U373-MAGI	Antiviral assay	25 to 400 uM	2 to 72 hrs		Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 25 to 400 uM after 2 to 72 hrs by qPCR method	27117260
U373-MAGI	Antiviral assay	25 to 400 uM	2 to 72 hrs		Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 25 to 400 uM after 2 to 72 hrs by qPCR method	27117260
L1210	Cytotoxicity assay				Cytotoxicity against mouse L1210 cells assessed as cessation of growth	69026
TC32	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
A673	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
BT-37	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
BT-12	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
NB1643	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
SKM1-S	Apoptosis assay	1 uM			Induction of apoptosis in human SKM1-S cells assessed as caspase 3 cleavage at 1 uM by Western blot method	28094938
MCF7	Function assay	15 uM	72 hrs		Inhibition of UHRF1 in human MCF7 cells assessed as decrease in methylation at RAR beta exon at 15 uM after 72 hrs by methylation specific-PCR method	27049577
Click to View More Cell Line Experimental Data

Mechanism of Action

Description

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro
In vitro	Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]
Cell Research	Cell lines	Leukemia L1210 cell
	Concentrations	0.15 μg/mL
	Incubation Time	3 days
	Method	5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
Experimental Result Images	Methods	Biomarkers	Images	PMID
	Western blot	DNMT1 c-PARP / p-H2AX / H2AX		28210112
	Immunofluorescence	HMGB1		29097772
	Growth inhibition assay	Cell viability		28210112

In Vivo
In vivo	Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]
Animal Research	Animal Models	BDF1 mice bearing lymphoid leukemia L1210
	Dosages	3 mg/kg
	Administration	Daily i.p. injection

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06372717	Not yet recruiting	Acute Myeloid Leukemia Refractory\|Myelodysplastic Syndrome Acute Myeloid Leukemia\|Myelodysplastic Syndrome With Excess Blasts\|Acute Myeloid Leukemia in Relapse	Apollo Therapeutics Ltd	April 2024	Phase 1\|Phase 2
NCT06263387	Not yet recruiting	AML Adult	French Innovative Leukemia Organisation\|Acute Leukemia French Association	April 29 2024	--
NCT06159491	Not yet recruiting	Chronic Myelomonocytic Leukemia	Douglas Tremblay\|Sobi Inc.\|Icahn School of Medicine at Mount Sinai	January 2 2024	Phase 1\|Phase 2
NCT06022003	Recruiting	AML Adult\|Refractory AML\|Relapsed Adult AML\|FLT3-TKD Mutation\|FLT3-ITD	French Innovative Leukemia Organisation\|Acute Leukemia French Association	January 13 2024	Phase 2
NCT06014489	Recruiting	AML Adult	Stichting Hemato-Oncologie voor Volwassenen Nederland	January 17 2024	Phase 2

References
https://pubmed.ncbi.nlm.nih.gov/12154409/ https://pubmed.ncbi.nlm.nih.gov/6173384/ https://pubmed.ncbi.nlm.nih.gov/5487063/ https://pubmed.ncbi.nlm.nih.gov/4118428/ + Expand

References

https://pubmed.ncbi.nlm.nih.gov/12154409/
https://pubmed.ncbi.nlm.nih.gov/6173384/
https://pubmed.ncbi.nlm.nih.gov/5487063/

https://pubmed.ncbi.nlm.nih.gov/4118428/

+ Expand

Chemical Information

Molecular Weight	244.2	Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2	SDF	Download Azacitidine (5-Azacytidine) SDF
Synonyms	5-AzaC,Ladakamycin, AZA,5-Aza, CC-486,NSC 102816,5-Azacytidine
Smiles	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N

Storage and Stability

Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
			1 month-20°Cin solvent

In vitro
Batch:

DMSO : 48 mg/mL ( (196.56 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molecular Weight Calculator

In vivo Batch: Add solvents to the product individually and in order.				In vivo Formulation Calculator
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 30%PEG300 2 65%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (40.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clarified DMSO stock solution to 300 μL of PEG 300, mix evenly to clarify it; then continue to add 650 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	16% DMSO 1 84% saline Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.781mg/ml (3.20mM)	Taking the 1 mL working solution as an example, add 160 μL of 4.88 mg/ml clear DMSO stock solution to 840 μL of saline and mix evenly. The mixed solution should be used immediately for optimal results.

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):